Find Funding Opportunities

This Funding Opportunity Announcement (FOA) is dedicated to the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, and cell therapies) for disorders that fall under the NINDS mission. An identified candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to the CREATE Bio Development Track. The FOA supports Investigational New Drug (IND)-enabling studies for the candidate and early-phase clinical trials. At the end of the funding period, a successful project should have an IND application submitted to the U.S. Food and Drug Administration (FDA), at a minimum. The program supports early-phase clinical trials, although these are not required.

This Funding Opportunity Announcement (FOA) is dedicated to the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, and cell therapies) for disorders that fall under the NINDS mission.An identified candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to the CREATE Bio Development Track. The FOA supports Investigational New Drug (IND)-enabling studies for the candidate and early-phase clinical trials. At the end of the funding period, a successful project should have an IND application submitted to the U.S. Food and Drug Administration (FDA), at a minimum.The program supports early-phase clinical trials, although these are not required.

This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate collaborative research opportunities between investigators in the U.S. and China focused on research toward a cure for HIV/AIDS.

The purpose of this FOA is to support the Neuroscience Information Framework Infrastructure and Search for Lacunas/Gaps in Knowledge About the Nervous System.

The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.

This Funding Opportunity Announcement (FOA) invites applications to build on the data collected using the very well defined experimental protocols of the Human Connectome Project (HCP) (http://www.neuroscienceblueprint.nih.gov/connectome/). Applications are sought that will apply the Human Connectome data collection protocol to disease/disorder cohorts of interest to the Institutes and Centers that are participating in this FOA. These cohorts will be defined by the applicant and can include subjects with specific symptoms or conditions, with comorbid conditions, with a specific genetic profile, or other applicant defined criteria.

This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications from institutions/ organizations that propose research relevant to the basic understanding and development of therapeutic interventions for currently screened conditions and high priority genetic conditions for which screening could be possible in the near future.In this FOA, a high priority condition is one for which the development of an efficacious therapy would make the condition amenable to newborn screening.

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory clinical trial applications to the newly authorized Direct-to-Phase II SBIR grant mechanism.The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, RandD that is characteristic of Phase-I (R43) SBIR projects.The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type RandD, to expand RandD opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization.

The National Institutes of Health (NIH), through its Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society.Toward meeting this objective, the NIH is collaborating with the National Science Foundation (NSF) to help accelerate the commercialization of early stage biomedical technologies by leveraging the NSF's established I-Corps team training program, which is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace.Under this funding opportunity announcement (FOA), participating NIH Institutes and Centers will provide administrative supplement awards to a pilot cohort of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps Team Training Pilot Program at the NIH.The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH SBIR and STTR funding.It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies.Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about this pilot program before applying.